IDYA IDEAYA Biosciences, Inc.
$33.50▲ +1.89%
Healthcare
Other
After hours
$33.50▲ +0.00%
Oct 27, 4:00 PM ET
Volume 1.00M
Avg Volume (10D) 938.3K
Key Metrics & Fundamentals
Market Cap
$3.23B
P/E Ratio
–
Div Yield
0.00%
52W Range
26.81 - 42.68
% vs 50 MA
-10.87%
% vs 200 MA
-1.67%
RSI-14
39.2
MACD Histogram
-0.0800
Beta (1Y vs SPY)
0.84
Free Cash Flow
-$89.08M
Gross Rev
$8.86M
Gross Profit
$8.86M
EBITDA
-$121.17M
COGS
–
Operating Exp
$131.15M
Operating Income
-$122.29M
EBIT
-$122.29M
Pretax Income
-$112.45M
Net Income
-$112.45M
EPS (Diluted)
-1.22
Price & Volume History
Loading chart…
Recent News
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks · Oct 27, 2026 9:00 AM ET
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
PR Newswire · Oct 23, 2026 6:00 AM ET
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Ideaya's PRMT5, MAT2A Programs Draw Investor Focus, RBC Says
MT Newswires · Oct 19, 2026 11:13 AM ET
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
PR Newswire · Oct 19, 2026 6:00 AM ET
William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating
MT Newswires · Oct 16, 2026 7:52 AM ET
IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
Simply Wall St. · Oct 8, 2026 1:18 PM ET
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
PR Newswire · Sep 28, 2026 6:00 AM ET
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
Insider Monkey · Sep 27, 2026 9:25 PM ET
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Sep 25, 2026 6:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See IDYA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.